ATE319730T1 - Neue kristallforme von azithromycin - Google Patents

Neue kristallforme von azithromycin

Info

Publication number
ATE319730T1
ATE319730T1 AT02726369T AT02726369T ATE319730T1 AT E319730 T1 ATE319730 T1 AT E319730T1 AT 02726369 T AT02726369 T AT 02726369T AT 02726369 T AT02726369 T AT 02726369T AT E319730 T1 ATE319730 T1 AT E319730T1
Authority
AT
Austria
Prior art keywords
azithromycin
crystal forms
new crystal
new
forms
Prior art date
Application number
AT02726369T
Other languages
German (de)
English (en)
Inventor
Zheng Jane Li
Andrew Vincent Trask
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE319730(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE319730T1 publication Critical patent/ATE319730T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT02726369T 2001-05-22 2002-05-01 Neue kristallforme von azithromycin ATE319730T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29256501P 2001-05-22 2001-05-22
US29774101P 2001-06-12 2001-06-12
US34304101P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
ATE319730T1 true ATE319730T1 (de) 2006-03-15

Family

ID=27404135

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02726369T ATE319730T1 (de) 2001-05-22 2002-05-01 Neue kristallforme von azithromycin
AT06110765T ATE404575T1 (de) 2001-05-22 2002-05-01 Neue kristallforme von azithromycin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06110765T ATE404575T1 (de) 2001-05-22 2002-05-01 Neue kristallforme von azithromycin

Country Status (35)

Country Link
US (10) US6977243B2 (enExample)
EP (1) EP1390377B1 (enExample)
JP (3) JP2004530703A (enExample)
KR (1) KR100574153B1 (enExample)
AP (1) AP2003002906A0 (enExample)
AR (1) AR036022A1 (enExample)
AT (2) ATE319730T1 (enExample)
AU (1) AU2002256846B2 (enExample)
BG (1) BG108370A (enExample)
BR (1) BR0209918A (enExample)
CA (1) CA2391659C (enExample)
CR (1) CR7159A (enExample)
CZ (1) CZ20033154A3 (enExample)
DE (2) DE60209704T2 (enExample)
DK (1) DK1390377T3 (enExample)
EA (2) EA009611B1 (enExample)
EE (1) EE200300575A (enExample)
ES (2) ES2310886T3 (enExample)
GE (1) GEP20084399B (enExample)
HU (1) HUP0400446A2 (enExample)
IL (1) IL158591A0 (enExample)
IS (1) IS7007A (enExample)
MA (1) MA27023A1 (enExample)
MX (1) MXPA03010028A (enExample)
MY (1) MY129319A (enExample)
NO (2) NO321894B1 (enExample)
NZ (2) NZ539801A (enExample)
PA (1) PA8545701A1 (enExample)
PE (1) PE20021064A1 (enExample)
PL (1) PL367091A1 (enExample)
PT (1) PT1390377E (enExample)
SK (1) SK14402003A3 (enExample)
TN (1) TNSN03121A1 (enExample)
WO (1) WO2002094843A1 (enExample)
YU (1) YU91603A (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
EP1152765B1 (en) * 1998-11-30 2004-10-13 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
CA2419873A1 (en) * 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
EP1390377B1 (en) * 2001-05-22 2006-03-08 Pfizer Products Inc. New crystal form of azithromycin
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
JP2005513099A (ja) 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
NZ532063A (en) * 2001-12-21 2006-03-31 Pfizer Prod Inc Methods for wet granulating azithromycin
NZ534234A (en) 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
CA2422972A1 (en) * 2003-03-21 2004-09-21 Apotex Inc. Isopropanolate of azithromycin and method of manufacturing
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1878432A1 (en) * 2003-07-24 2008-01-16 Pliva - Research and Development Ltd. Single dose fast dissolving azithromycin
US7572773B2 (en) 2003-07-24 2009-08-11 Pliva Hrvatska D.O.O. Single dose fast dissolving azithromycin
CN1894251B (zh) * 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20050250714A1 (en) * 2004-05-06 2005-11-10 Lin Kangwen L Crystalline forms of 9-(S)-erythromycylamine
EP1776365B1 (en) * 2004-06-02 2011-08-03 Sandoz Ag Meropenem intermediate in crystalline form
US7683162B2 (en) 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US8495244B2 (en) * 2005-06-29 2013-07-23 Jumpstart Wireless Corporation System and method for dynamic automatic communication path selection, distributed device synchronization and task delegation
US7750153B2 (en) * 2005-07-05 2010-07-06 Hetero Drugs Limited Process for the preparation of didanosine using novel intermediates
EP1904510A1 (en) * 2005-07-14 2008-04-02 Pfizer Products Incorporated Process for forming amorphous azithromycin particles
KR101314158B1 (ko) * 2005-09-21 2013-10-04 4에스체 악티엔게젤샤프트 히스톤 탈아세틸 효소 억제제로서의 설포닐피롤 염산염
CN101389617A (zh) * 2005-10-31 2009-03-18 詹森药业有限公司 制备哌嗪基和二氮杂环庚烷基苯甲酰胺衍生物的新方法
US8558765B2 (en) * 2005-11-07 2013-10-15 Global Oled Technology Llc Method and apparatus for uniformity and brightness correction in an electroluminescent display
US8299095B2 (en) * 2006-06-16 2012-10-30 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US7919676B2 (en) 2007-08-03 2011-04-05 Pioneer Hi-Bred International, Inc. Msca1 nucleotide sequences impacting plant male fertility and method of using same
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
US8216363B2 (en) * 2008-10-27 2012-07-10 Illinois Institute Of Technology Continuous antisolvent crystallization process and system using plug flow reactors
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
MX2011009548A (es) 2009-03-13 2011-12-14 Da Volterra Composiciones y metodos para la eliminacion de bacterias gram-negativas.
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2544679B1 (en) 2010-03-12 2019-05-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
SG10201506865WA (en) * 2010-09-01 2015-10-29 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
EP2760859A1 (en) * 2011-09-30 2014-08-06 Sunshine Lake Pharma Co., Ltd Crystalline forms of azilsartan and preparation and uses thereof
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
RU2017134509A (ru) 2015-04-24 2019-04-04 Омерос Корпорейшн Ингибиторы pde10 и соответствующие композиции и способы
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
FI3679016T3 (fi) * 2017-09-07 2025-12-12 Atnx Spv Llc 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43116B (en) 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4465674A (en) 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4983531A (en) * 1990-02-12 1991-01-08 Motorola, Inc. Method of fabricating a single polysilicon bipolar transistor which is compatible with a method of fabricating CMOS transistors
CN1034734C (zh) 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
CN1093370A (zh) * 1993-12-10 1994-10-12 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
IL127833A (en) * 1996-07-29 2004-06-20 Abbott Lab Preparation of the crystalline form II of clarithromycin
CN1161971A (zh) 1997-01-03 1997-10-15 石家庄制药集团有限公司 一种阿齐霉素结晶及其制备方法
PT102130A (pt) 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
EP1152765B1 (en) * 1998-11-30 2004-10-13 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
DE60029589T2 (de) * 1999-06-29 2007-07-19 Sandoz Ag Verfahren zur herstellung von azithromycin
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
DE60133083D1 (de) 2000-01-04 2008-04-17 Teva Pharma Verfahren zur herstellung von azithromycin-dihydrat
ES2162764B1 (es) 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
WO2002007736A1 (en) 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
ATE320441T1 (de) 2000-07-25 2006-04-15 Silanes Sa De Cv Lab Einstufiges verfahren zur herstellung von 7,16-
ITBO20000471A1 (it) 2000-07-31 2002-01-31 Vieri Ridolfi Dispositivo di supporto per prodotti da fumo particolarmente sigarette .
ES2172417B1 (es) 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
CA2419873A1 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
PL207076B1 (pl) 2000-11-27 2010-10-29 Sandoz Ag Sposób wytwarzania jednowodzianu azytromycyny
IN190080B (enExample) 2001-01-29 2003-06-07 Alembic Ltd
KR100431431B1 (ko) 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
EP1390377B1 (en) * 2001-05-22 2006-03-08 Pfizer Products Inc. New crystal form of azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DK1446010T3 (da) 2001-10-18 2009-06-22 Teva Pharma Stabiliseret azithromycin-sammensætning

Also Published As

Publication number Publication date
DE60228345D1 (de) 2008-09-25
EE200300575A (et) 2004-04-15
EP1390377A1 (en) 2004-02-25
DE60209704T2 (de) 2006-11-16
WO2002094843A1 (en) 2002-11-28
PL367091A1 (en) 2005-02-21
TNSN03121A1 (en) 2005-12-23
PA8545701A1 (es) 2003-09-05
US20050192234A1 (en) 2005-09-01
IS7007A (is) 2003-10-30
ES2258142T3 (es) 2006-08-16
NZ539801A (en) 2006-10-27
NZ529118A (en) 2005-10-28
PE20021064A1 (es) 2002-11-21
US7282486B2 (en) 2007-10-16
JP2004530703A (ja) 2004-10-07
DE60209704D1 (de) 2006-05-04
ATE404575T1 (de) 2008-08-15
US20050256063A1 (en) 2005-11-17
US7307156B2 (en) 2007-12-11
CZ20033154A3 (en) 2004-04-14
US7105179B2 (en) 2006-09-12
US20030162730A1 (en) 2003-08-28
BG108370A (bg) 2004-11-30
NO20061049L (no) 2003-05-12
EP1390377B1 (en) 2006-03-08
EA200500630A1 (ru) 2006-02-24
HUP0400446A2 (hu) 2004-09-28
JP4584162B2 (ja) 2010-11-17
MY129319A (en) 2007-03-30
AR036022A1 (es) 2004-08-04
NO20035177D0 (no) 2003-11-21
US20040043944A1 (en) 2004-03-04
US20050090459A1 (en) 2005-04-28
IL158591A0 (en) 2004-05-12
US7053192B2 (en) 2006-05-30
NO321894B1 (no) 2006-07-17
CA2391659C (en) 2006-05-30
US7309782B2 (en) 2007-12-18
ES2310886T3 (es) 2009-01-16
US7081525B2 (en) 2006-07-25
BR0209918A (pt) 2004-03-30
CR7159A (es) 2004-02-23
JP2006152002A (ja) 2006-06-15
US6977243B2 (en) 2005-12-20
JP2007161726A (ja) 2007-06-28
KR20040014525A (ko) 2004-02-14
KR100574153B1 (ko) 2006-04-25
EA200301115A1 (ru) 2004-04-29
EA009611B1 (ru) 2008-02-28
AP2003002906A0 (en) 2003-12-31
YU91603A (sh) 2006-08-17
EA007618B1 (ru) 2006-12-29
MA27023A1 (fr) 2004-12-20
US20050245469A1 (en) 2005-11-03
US20040082527A1 (en) 2004-04-29
AU2002256846B2 (en) 2007-04-05
CA2391659A1 (en) 2002-11-22
US20050256062A1 (en) 2005-11-17
DK1390377T3 (da) 2006-06-19
GEP20084399B (en) 2008-06-10
US20040043945A1 (en) 2004-03-04
US20040138149A1 (en) 2004-07-15
SK14402003A3 (sk) 2004-06-08
MXPA03010028A (es) 2004-02-12
PT1390377E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
ATE319730T1 (de) Neue kristallforme von azithromycin
DE60239146D1 (de) Neue kristalline verbindung
DE60236581D1 (de) Ng von mosaikeffekten
DE60211601D1 (de) Bereitstellung von positionsabhängigen Inhalten
EP1372132A4 (en) SELF-LIGHTING DISPLAY
DE02784674T1 (de) Quantifizierung von polypeptiden
DE50212455D1 (de) Verwendung von Dimerdiolen
DE60219386D1 (de) Flüssigkristallanzeige
DE60227828D1 (de) E von schmelzkleber
DE60234074D1 (de) Flüssigkristallanzeige
DE60111435D1 (de) Flüssigkeitskühlung von Glasformen
DE60031450D1 (de) Polymorph v von torasemid
DE60007360T2 (de) Amorphe modifikation von torasemid
ATE293113T1 (de) Neue polymorphe formen von olanzapin
DE60211186D1 (de) Neue verwendung substituierter aminomethylchromane
DE50203067D1 (de) Quarzoszillatorschaltung
DE50109358D1 (de) Flüssigkristall-Anzeige
DE60208824D1 (de) Verbesserungen von elektromechanischen aktuatoren
DE50203046D1 (de) Verwendung von Esterquats
DE60206043D1 (de) Neue indolderivate
ATA5002002A (de) Vibrator
ATA14062001A (de) Fassung
FI20010970L (fi) Nestekoostumus
ATE348606T1 (de) Neue verwendung von pipatalin
DE60233952D1 (de) Neue serinprotease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1390377

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked